
Nirsevimab Reduces Medically Attended RSV-Associated Lower Respiratory Tract Infection and Hospitalisations in Healthy Pre-Term Infants 2022 Sarah Murphy PMID: 33597216DOI: https://dx.doi.org/10.1136/archdischild-2020-321141 Access Resources Journal ArticleEN Ask aRCie About This Resource About This article comments on a study on how nirsevimab helps reduce RSV-related lung infections and hospital visits in healthy pre-term infants. It highlights the benefits of using a single dose of nirsevimab to prevent these infections. The article is part of ongoing research to find better ways to protect young children from respiratory illnesses caused by RSV, aiming for safer health outcomes for vulnerable infants. Tags Focus Area: Infectious Disease Audience: Physicians Emergency Management Stage: Preparedness (Prevention / Protection) Bundles: Nirsevimab Library Keywords: Antibodies, Monoclonal; Hospitalization; Infant; Neonatology; Respiratory Syncytial Virus Infections; Respiratory Tract Infections; Therapeutics; Antibodies, Monoclonal, Humanized Institutions: University College Cork More like this Strategies for Improving Vaccine Communication and Uptake 2024 · American Academy of Pediatrics (AAP), University of Colorado, Seattle Children's Hospital, New York Medical College Nirsevimab Reduces Medically Attended RSV-Associated Lower Respiratory Trract Infection and Hospitalisations in Healthy Pre-Term Infants 2022 · University College Cork Diagnosis, Treatment, and Prevention of Monkeypox in Children: An Experts’ Consensus Statement 2023 · Capital Medical University, Shenzhen Children's Hospital, Chinese Center for Disease Control and Prevention, Chinese Academy of Medical Science & Peking Union Medical College, Beijing Children's Hospital The information provided on this website is for educational purposes only. It does not substitute for professional medical advice, diagnosis, or treatment. Always seek the advice of your physician or other qualified health provider with any questions you may have regarding a medical condition. Access Resources Journal ArticleEN Ask aRCie About This Resource

Nirsevimab Reduces Medically Attended RSV-Associated Lower Respiratory Tract Infection and Hospitalisations in Healthy Pre-Term Infants

2022
Sarah Murphy

PMID: 33597216DOI: https://dx.doi.org/10.1136/archdischild-2020-321141

Access Resources

About

This article comments on a study on how nirsevimab helps reduce RSV-related lung infections and hospital visits in healthy pre-term infants. It highlights the benefits of using a single dose of nirsevimab to prevent these infections. The article is part of ongoing research to find better ways to protect young children from respiratory illnesses caused by RSV, aiming for safer health outcomes for vulnerable infants.

More like this

Strategies for Improving Vaccine Communication and Uptake 2024 · American Academy of Pediatrics (AAP), University of Colorado, Seattle Children's Hospital, New York Medical College Nirsevimab Reduces Medically Attended RSV-Associated Lower Respiratory Trract Infection and Hospitalisations in Healthy Pre-Term Infants 2022 · University College Cork Diagnosis, Treatment, and Prevention of Monkeypox in Children: An Experts’ Consensus Statement 2023 · Capital Medical University, Shenzhen Children's Hospital, Chinese Center for Disease Control and Prevention, Chinese Academy of Medical Science & Peking Union Medical College, Beijing Children's Hospital

The information provided on this website is for educational purposes only. It does not substitute for professional medical advice, diagnosis, or treatment. Always seek the advice of your physician or other qualified health provider with any questions you may have regarding a medical condition.

Nirsevimab Reduces Medically Attended RSV-Associated Lower Respiratory Tract Infection and Hospitalisations in Healthy Pre-Term Infants

Access Resources

About

Tags

More like this

Access Resources